Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
November 10, 2008
- Eisai: Aricept, MGI Pharma's Products Push Up Sales 9.9%
November 10, 2008
- JSMI Adds 20 APIs as Candidates for Switch OTC Drugs
November 10, 2008
- MTPC: Sales Down 0.7% Despite Strong Growth of Remicade, Mearubik
November 10, 2008
- Taisho: Strong Self-med. Business Makes Up for Slump of Ethical Drugs Business
November 10, 2008
- DSP: New Products Make Up for Decreases in Sales of Amlodin
November 10, 2008
- SSP: Sales Remain Soft but Profits Jump
November 10, 2008
- Kyowa Hakko Kirin: Addition of Kirin Pharma Boosts Sales, Profits
November 10, 2008
- Nihon Chouzai, Matsumotokiyoshi to Ally to Open More Drugstores with Dispensing Services
November 10, 2008
- JT: Milestones Help Improve Pharmaceutical Business
November 10, 2008
- Council Recommends Early Approval of Intracranial Stent and Artificial Jaw Joint
November 10, 2008
- Torii: Business Hit by Generics of Futhan
November 10, 2008
- Eiken Chemical: Sales Up 2.9% but Full-year Profits Forecasts Revised Downward
November 10, 2008
- BUSINESS NEWS IN BRIEF
November 10, 2008
- MEDICAL DEVICE NEWS IN BRIEF
November 10, 2008
- Nippon Chemiphar: Sharp Drop in Profits Despite 5.8% Increase in Sales
November 10, 2008
- Colorectal Cancer Management GL to Be Revised in July 2009
November 10, 2008
- PMDA to Conduct More On-site Inspections Overseas for Generics
November 10, 2008
- GL in Preparation for Safer HRT
November 10, 2008
- COMMENTARY／Will World's Top Generic Maker Be Able to Succeed in Japan?
November 10, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…